DAWN — Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 181
• Website: https://dayonebio.com

Latest SEC filings for DAWN

• 15-12G — 2026-05-04
• SC TO-T/A — 2026-04-23
• S-8 POS — 2026-04-23
• S-8 POS — 2026-04-23
• S-8 POS — 2026-04-23
• 25-NSE — 2026-04-23
• POSASR — 2026-04-23
• S-8 POS — 2026-04-23
• POSASR — 2026-04-23
• 8-K — 2026-04-23

Abrir análisis completo

Educational tool only — not investment advice.